U.S. immigration focuses on U.S. business immigration: Recently, Watson Bio reached a consensus with Medidata Corporation (referred to as "Medidata") on enhancing the company's data management capabilities for drug clinical research and further accelerating the progress of the company's drug clinical studies. They signed the "Medidata Service Agreement" and simultaneously signed three sales orders (specific project cooperation agreements), agreeing to collaborate on the clinical research of the company's 13-valent pneumococcal polysaccharide conjugate vaccine.
It is understood that Medidata is a global leader in cloud solutions for clinical research in the life sciences field, improving clinical development through advanced applications and electronic data analysis. It is dedicated to providing the most advanced tools for all participants in clinical trials to plan and manage clinical trials, shortening development cycles, reducing risks, and lowering costs, assisting global clients in advancing their market competitiveness and scientific research goals. Medidata's clients include over 90% of the top 25 pharmaceutical companies, innovative biotechnology firms, diagnostic and device companies, as well as leading academic medical centers and contract research organizations (CROs).
Watson Bio stated that the signing of the agreement will facilitate cooperation between the two parties in the field of drug clinical research, fully leveraging Medidata's professional advantages to help the company improve clinical trial efficiency and meet international clinical trial standards, enhance the company's data management capabilities for drug clinical research, ensure compliance and efficiency in advancing clinical trial processes, and accelerate the company's product development process to achieve early market launch and sales of the company's products.
